{"organizations": ["Resverlogix Eastern Capital", "Eastern Capital"], "uuid": "d0d630d1dc263e9f628743c7d45b0084302eacb7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530530?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Eastern Capital invests $Cdn15mm in Resverlogix", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Eastern Capital invests $Cdn15mm in Resverlogix", "spam_score": 0.0, "site_type": "news", "published": "2015-07-08T02:30:00.000+03:00", "replies_count": 0, "uuid": "d0d630d1dc263e9f628743c7d45b0084302eacb7"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530530?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Eastern Capital invests $Cdn15mm in Resverlogix", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Eastern Capital invests $Cdn15mm in Resverlogix Deal Date: Jun-01-2015 / Deal # 201530530 Executive Summary \nExisting stockholder Eastern Capital invested $Cdn15mm ($12mm) in Resverlogix Corp. (epigenetics platform that generates bromodomain and extraterminal (BET) domain inhibitors for atherosclerosis, diabetes, Alzheimer's, chronic kidney disease, and peripheral artery disease). Eastern purchased 5.6mm shares at $Cdn2.67, an 18% premium, and received five-year warrants to buy 422k shares for $Cdn2.67. Post-transaction, Eastern owns approximately 20.6mm Resverlogix shares, increasing its stake from 17.3% to 23.87%.", "external_links": [], "published": "2015-07-08T02:30:00.000+03:00", "crawled": "2015-07-08T14:06:29.000+03:00", "highlightTitle": ""}